4D Molecular Therapeutics, Inc. Common Stock
Symbol: FDMT (NASDAQ)
6.38
▲ (41.76%) 1.879
Company Description:
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Key Stats
- Today's Open: $6.04
- Today's High: $6.671
- Today's Low: $5.918
- Today's Volume: 9.79M
- Yesterday Close: $4.5
- Yesterday High: $4.61
- Yesterday Low: $4.3
- Yesterday Volume: 2.30M
- Last Min Volume: 0
- Last Min High: $6.379
- Last Min Low: $6.374
- Last Min VWAP: $0
Company Profile
- Name: 4D Molecular Therapeutics, Inc. Common Stock
- Website: https://www.4dmoleculartherapeutics.com
- Listed Date: 2020-12-11
- Location: EMERYVILLE, CA
- Market Status: Active
- CIK Number: 0001650648
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $208.46M
- Round Lot: 100
- Outstanding Shares: 46.32M
- Asset Type: CS
RECENT FILINGS FOR FDMT
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-07-02 | 8-K | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-08 | S-8 | View |
| 2025-05-08 | 10-Q | View |
| 2025-05-08 | 8-K | View |
| 2025-04-29 | ARS | View |
| 2025-04-29 | DEFA14A | View |
| 2025-04-29 | DEF 14A | View |
| 2025-04-17 | SCHEDULE 13G/A | View |
| 2025-03-24 | EFFECT | View |
| 2025-03-10 | 4 | View |
| 2025-03-10 | 4 | View |
Latest News on FDMT